Editas Medicine, Inc. · NASDAQ:EDIT

Editas Medicine — American Heart Association Scientific Sessions 2026

15 slides from Editas Medicine's conference presentation, November 2026

  1. Slide 1: EDIT-401: In Vivo Gene Editing to Enhance LDLR Function for Durable LDL-C Reduction

    Slide 1: EDIT-401: In Vivo Gene Editing to Enhance LDLR Function for Durable LDL-C Reduction

    EDIT-401: IN VIVO GENE EDITING TO ENHANCE LDLR FUNCTION FOR DURABLE LDL-C REDUCTION Daniel Ory, MD | Chief Medical Officer, Editas Medicine #ScientificSessions26

  2. Slide 2: Disclosure Slide

    Slide 2: Disclosure Slide

    DISCLOSURE SLIDE This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘in tend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’

  3. Slide 3: Editas Medicine: A Differentiated Genetic Medicine Engine

    Slide 3: Editas Medicine: A Differentiated Genetic Medicine Engine

    EDITAS MEDICINE: A DIFFERENTIATED GENETIC MEDICINE ENGINE Accessible, Durable Medicines: Single-dose, Lifelong Benefit Harness gene editing to Challenge the unlock new possibilities, status quo and change Establish a Realize the such as increasing levels the course of disease New Unique of disease-m

  4. Slide 4: Lower LDL-C Is Better in Patients with ASCVD

    Slide 4: Lower LDL-C Is Better in Patients with ASCVD

    LOWER LDL-C IS BETTER IN PATIENTS WITH ASCVD Continuous relationship between LDL-C lowering and reduced risk of CV events2 • LDL-C is the foundational marker of CV event probability (%) ASCVD risk,1 and risk of CV events continues to decrease with lower LDL-C levels2,3 • Guidelines recommend aggress

  5. Slide 5: Therapeutic Strategy of LDLR Upregulation Is Informed by Human Genetics

    Slide 5: Therapeutic Strategy of LDLR Upregulation Is Informed by Human Genetics

    THERAPEUTIC STRATEGY OF LDLR UPREGULATION FOR LDL-C REDUCTION IS INFORMED BY HUMAN GENETICS Seven Icelandic family members were identified as carriers of partial LDLR 3' UTR deletion1 Similar deletions have been identified in families in France and the UK 2 Plasma LDL-C levels1 Impact on carriers1 3

  6. Slide 6: EDIT-401 Uses a Differentiated Mechanism of Action to Reduce LDL-C

    Slide 6: EDIT-401 Uses a Differentiated Mechanism of Action to Reduce LDL-C

    EDIT-401 USES A DIFFERENTIATED MECHANISM OF ACTION TO REDUCE LDL-C EDIT-401 therapeutic strategy for LDLR upregulation • LDLR upregulation strategy targets functional alleles rather than correcting a deficient gene • LDLR upregulation is achieved by disrupting negative regulatory elements of the LDL

  7. Slide 7: Single Dose of EDIT-401 Evaluated Across NHP Studies

    Slide 7: Single Dose of EDIT-401 Evaluated Across NHP Studies

    SINGLE DOSE OF EDIT-401 EVALUATED ACROSS NHP STUDIES PD/Biomarker Endpoints NHP Study Design 1. LDL-C levels 2. Lp(a) levels 3. ApoB levels Vehicle Control Safety Endpoints 1. Tolerability assessment Single Dose 2. Liver function test 3. Histopathology EDIT-401 Dose Range: PK/Biodistribution EDIT-40

  8. Slide 8: Robust, Dose-Dependent, and Durable LDL-C Reduction Following a Single Dose

    Slide 8: Robust, Dose-Dependent, and Durable LDL-C Reduction Following a Single Dose

    ROBUST, DOSE-DEPENDENT, AND DURABLE LDL-C REDUCTION FOLLOWING A SINGLE DOSE OF EDIT-401 ≥90% mean LDL-C reduction at 10 months Vehicle 1.5 mg/kg 2 mg/kg 3 mg/kg 40 (n=4) (n=4) (n=4) (n=4) (mean % reduction from baseline) 30 20 10 0 -10 -20 LDL-C -30 -40 -50 -60 -70 -80 -90 -100 7 10 1 2 3 4 5 6 8 9

  9. Slide 9: Single Dose of EDIT-401 Lowers Multiple Atherogenic Lipoproteins

    Slide 9: Single Dose of EDIT-401 Lowers Multiple Atherogenic Lipoproteins

    SINGLE DOSE OF EDIT-401 LOWERS MULTIPLE ATHEROGENIC LIPOPROTEINS ~90% mean Lp(a) reduction at 3 months ~90% mean ApoB reduction at 3 months Vehicle 1.5 mg/kg 3 mg/kg 5 mg/kg 60 Vehicle 1.5 mg/kg 3 mg/kg 5 mg/kg (mean % reduction from baseline) 60 (n=8) (n=8) (n=8) (n=8) (mean % reduction from baseli

  10. Slide 10: No Adverse Liver Findings Following Single Dose of EDIT-401

    Slide 10: No Adverse Liver Findings Following Single Dose of EDIT-401

    NO ADVERSE LIVER FINDINGS FOLLOWING SINGLE DOSE OF EDIT-401 • Transient ALT elevations • No bilirubin elevations • No histopathologic changes Mean (SD) ALT Mean (SD) Bilirubin 600 1.0 Vehicle Vehicle 1.5 mg/kg 0.9 1.5 mg/kg 500 0.8 0.7 400 0.6 Units/L Units/L 300 0.5 0.4 200 0.3 0.2 100 0.1 0 0.0 D8

  11. Slide 11: EDIT-401 Provides Targeted Delivery to the Liver with No Evidence of Genotoxicity

    Slide 11: EDIT-401 Provides Targeted Delivery to the Liver with No Evidence of Genotoxicity

    EDIT-401 PROVIDES TARGETED DELIVERY TO THE LIVER WITH NO EVIDENCE OF GENOTOXICITY EDIT-401 delivers liver-targeted editing ✱✱✱✱ 25% Vehicle • High delivery to hepatocytes with 20% 1.5 mg/kg undetectable Cas9 mRNA in 15% oocytes* % indels • No off-target editing detected in 10% a panel of ~1500 candi

  12. Slide 12: Phase 1/2 Study Design to Evaluate Safety and Efficacy of EDIT-401

    Slide 12: Phase 1/2 Study Design to Evaluate Safety and Efficacy of EDIT-401

    PHASE 1/2 STUDY DESIGN TO EVALUATE SAFETY AND EFFICACY OF EDIT-401 FOR LOWERING LDL-C LONG-TERM PART 1 | 2-year follow-up PART 2 | 2-year follow-up EXTENSION Dose ranging & safety study Dose expansion & efficacy study Single ascending IV dose 3:1 randomization (n=20) Adults with HeFH Up to 6 cohorts

  13. Slide 13: Conclusions

    Slide 13: Conclusions

    CONCLUSIONS • EDIT-401 has demonstrated dose-dependent mean reductions of ~90% in LDL-C, ApoB, and Lp(a), and a consistent safety profile in non-clinical studies to date • EDIT-401 presents a potential best-in-class, one-time treatment opportunity for patients with hypercholesterolemia to reduce LDL

  14. Slide 14: Thank You

    Slide 14: Thank You

    THANK YOU #ScientificSessions26

  15. Slide 15: Acknowledgments

    Slide 15: Acknowledgments

    ACKNOWLEDGMENTS Nonclinical Development Discovery Genomics & Bioinformatics Clinical/Program Parth Amin Luis Agosto Nassim Ajami Management Jonathan Carey Ameya Apte Jim Bochicchio Thrusha Chauhan Ruhong Dong Linda Burkly Meredith Chamberlin Larissa Collins Anshul Gupta Benjamin Diner Samira Ibrahim

Source: company website

More decks from Editas Medicine, Inc.

All 26 Editas Medicine decks